Role of metformin in various pathologies: state-of-the-art microcapsules for improving its pharmacokinetics

被引:11
作者
Gedawy, Ahmed [1 ]
Al-Salami, Hani [2 ]
Dass, Crispin R. [1 ,3 ]
机构
[1] Curtin Univ, Sch Pharm & Biomed Sci, Bentley, WA 6102, Australia
[2] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm & Biomed Sci, Biotechnol & Drug Dev Res Lab, Bentley, WA 6102, Australia
[3] Curtin Hlth Innovat Res Inst, Bentley, WA 6102, Australia
基金
欧盟地平线“2020”;
关键词
aging; Alzheimer's; biomarkers; new materials; cancer; diabetes; inflammation; metformin; microcapsules; oxidative stress; pharmacokinetics; ACTIVATED PROTEIN-KINASE; DIABETES-MELLITUS; ENDOTHELIAL FUNCTION; MUCOADHESIVE BEADS; IN-VITRO; CLINICAL PHARMACOKINETICS; OXIDATIVE-PHOSPHORYLATION; INSULIN-RESISTANCE; ANTIDIABETIC DRUGS; CONTROLLED-RELEASE;
D O I
10.4155/tde-2020-0102
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metformin was originally derived from a botanical ancestry and became the most prescribed, first-line therapy for Type 2 diabetes in most countries. In the last century, metformin was discovered twice for its antiglycemic properties in addition to its antimalarial and anti-influenza effects. Metformin exhibits flip-flop pharmacokinetics with limited oral bioavailability. This review outlines metformin pharmacokinetics, pharmacodynamics and recent advances in polymeric particulate delivery systems as a potential tool to target metformin delivery to specific tissues/organs. This interesting biguanide is being rediscovered this century for multiple clinical indications as anticancer, anti-aging, anti-inflammatory, anti-Alzheimer's and much more. Microparticulate delivery systems of metformin may improve its oral bioavailability and optimize the therapeutic goals expected.
引用
收藏
页码:733 / 753
页数:22
相关论文
共 174 条
[1]   Microencapsulation Approach for Orally Extended Delivery of Glipizide: In vitro and in vivo Evaluation [J].
Abdelbary, A. ;
El-Gendy, N. A. ;
Hosny, A. .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 74 (04) :319-330
[2]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[3]   Metformin: an old but still the best treatment for type 2 diabetes [J].
Aguayo Rojas, Lilian Beatriz ;
Gomes, Marilia Brito .
DIABETOLOGY & METABOLIC SYNDROME, 2013, 5
[4]  
Akin-Ajani O. D., 2019, Journal of Excipients and Food Chemicals, V10, P3
[5]   Glycemic Targets: Standards of Medical Care in Diabetes-2020 [J].
不详 .
DIABETES CARE, 2020, 43 :S66-S76
[7]  
Amod A, 2020, DIABETES THER, V11, P53, DOI [10.1007/s13300-019-00715-x, 10.2337/dci19-0066]
[8]  
Andrzejewski S, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-12
[9]   Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels [J].
Anedda, Andrea ;
Rial, Eduardo ;
Gonzalez-Barroso, M. Mar .
JOURNAL OF ENDOCRINOLOGY, 2008, 199 (01) :33-40
[10]   Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice [J].
Anisimov, VN ;
Berstein, LM ;
Egormin, PA ;
Piskunova, TS ;
Popovich, IG ;
Zabezhinski, MA ;
Kovalenko, IG ;
Poroshina, TE ;
Semenchenko, AV ;
Provinciali, M ;
Re, F ;
Franceschi, C .
EXPERIMENTAL GERONTOLOGY, 2005, 40 (8-9) :685-693